InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,622.24
(
0.02%
)
US TECH 100
19,285.60
(
-0.07%
)
Dow Jones
40,847.45
(
-0.11%
)
Brent Oil
76.70
(
1.33%
)
Bitcoin
60,714.40
(
2.89%
)
Post# of 252943
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120317
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 89527

Thursday, 02/17/2011 6:52:29 PM

Thursday, February 17, 2011 6:52:29 PM

Post# of 252943
Conatus starts phase-2b trial in HCV null-responders:

http://finance.yahoo.com/news/Conatus-Pharmaceuticals-prnews-802390242.html?x=0&.v=1

This is possibly the oddest HCV program I know of. Conatus, who is private, seems to not quite be sure if CTS-1027 is an antiviral drug or something else. For background, please see the embedded links in #msg-46034554.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up